Editas Medicine (EDIT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.35, -3.69% vs the prior close of $2.44.
- Volume 1.55M shares, 0.5x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
EDIT slides 3.7% to $2.35. Closed at $2.35, -3.69% vs the prior close of $2.44. Day range $2.33–$2.47, opened at $2.44.
EDIT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — EDIT slides 3.7% to $2.35
- Closed at $2.35, -3.69% vs the prior close of $2.44. Day range $2.33–$2.47, opened at $2.44.
- Volume was 1.55M shares, 0.5x its 50-day average of 2.87M — lighter than usual.
- Price is -16.7% vs its 50-day average ($2.82) and -11.5% vs its 200-day average ($2.66).
- 52-week range $1.66–$4.33; today's close sits at 26% of that range, 45.7% below the 52-week high.
Oct 15, 2026 — EDIT jumps 7.5% to $2.44
- Closed at $2.44, +7.49% vs the prior close of $2.27. Day range $2.25–$2.46, opened at $2.26.
- Volume was 1.86M shares, 0.6x its 50-day average of 2.87M.
- Price is -13.9% vs its 50-day average ($2.83) and -8.1% vs its 200-day average ($2.65).
- 52-week range $1.66–$4.33; today's close sits at 29% of that range, 43.6% below the 52-week high.
Oct 14, 2026 — EDIT slides 7.2% to $2.27, a 6-month low, 3 down days in a row
- Closed at $2.27, -7.16% vs the prior close of $2.44. Day range $2.24–$2.47, opened at $2.44.
- Volume was 2.83M shares, 1.0x its 50-day average of 2.84M.
- Price is -20.0% vs its 50-day average ($2.84) and -14.4% vs its 200-day average ($2.65).
- 52-week range $1.66–$4.33; today's close sits at 23% of that range, 47.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — EDIT slides 11.1% to $2.44, a 3-month low
- Closed at $2.44, -11.09% vs the prior close of $2.75. Day range $2.44–$2.73, opened at $2.73.
- Volume was 2.45M shares, 0.9x its 50-day average of 2.81M.
- Price is -14.2% vs its 50-day average ($2.85) and -7.8% vs its 200-day average ($2.65).
- 52-week range $1.66–$4.33; today's close sits at 29% of that range, 43.5% below the 52-week high.
Oct 12, 2026 — EDIT slides 5.2% to $2.75
- Closed at $2.75, -5.17% vs the prior close of $2.90. Day range $2.73–$2.91, opened at $2.90.
- Volume was 1.30M shares, 0.5x its 50-day average of 2.81M — lighter than usual.
- Price is -3.6% vs its 50-day average ($2.85) and +3.7% vs its 200-day average ($2.65).
- 52-week range $1.66–$4.33; today's close sits at 41% of that range, 36.5% below the 52-week high.
Oct 9, 2026 — EDIT rises 2.1% to $2.90, 3 up days in a row
- Closed at $2.90, +2.11% vs the prior close of $2.84. Day range $2.71–$2.97, opened at $2.85.
- Volume was 3.09M shares, 1.1x its 50-day average of 2.76M.
- Price is +1.8% vs its 50-day average ($2.85) and +9.5% vs its 200-day average ($2.65).
- 52-week range $1.66–$4.33; today's close sits at 46% of that range, 33.0% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — EDIT jumps 3.3% to $2.84 on 2.3x normal volume
- Closed at $2.84, +3.27% vs the prior close of $2.75. Day range $2.69–$2.94, opened at $2.79.
- Volume was 6.07M shares, 2.3x its 50-day average of 2.67M — unusually heavy trading.
- Price is -0.2% vs its 50-day average ($2.84) and +7.3% vs its 200-day average ($2.65).
- 52-week range $1.66–$4.54; today's close sits at 41% of that range, 37.4% below the 52-week high.
- SEC filings that day: 8-K.
Oct 7, 2026 — EDIT rises 0.7% to $2.75
- Closed at $2.75, +0.73% vs the prior close of $2.73. Day range $2.66–$2.85, opened at $2.71.
- Volume was 2.26M shares, 0.9x its 50-day average of 2.66M.
- Price is -3.2% vs its 50-day average ($2.84) and +4.0% vs its 200-day average ($2.64).
- 52-week range $1.66–$4.54; today's close sits at 38% of that range, 39.4% below the 52-week high.
Oct 6, 2026 — EDIT dips 2.2% to $2.73
- Closed at $2.73, -2.15% vs the prior close of $2.79. Day range $2.71–$2.89, opened at $2.85.
- Volume was 2.97M shares, 1.1x its 50-day average of 2.62M.
- Price is -3.8% vs its 50-day average ($2.84) and +3.4% vs its 200-day average ($2.64).
- 52-week range $1.66–$4.54; today's close sits at 37% of that range, 39.8% below the 52-week high.
Oct 5, 2026 — EDIT jumps 6.5% to $2.79
- Closed at $2.79, +6.49% vs the prior close of $2.62. Day range $2.56–$2.81, opened at $2.62.
- Volume was 3.01M shares, 1.2x its 50-day average of 2.59M.
- Price is -1.6% vs its 50-day average ($2.84) and +5.7% vs its 200-day average ($2.64).
- 52-week range $1.66–$4.54; today's close sits at 39% of that range, 38.5% below the 52-week high.
Oct 2, 2026 — EDIT jumps 4.0% to $2.62
- Closed at $2.62, +3.97% vs the prior close of $2.52. Day range $2.51–$2.63, opened at $2.57.
- Volume was 2.16M shares, 0.8x its 50-day average of 2.57M.
- Price is -7.5% vs its 50-day average ($2.83) and -0.7% vs its 200-day average ($2.64).
- 52-week range $1.66–$4.54; today's close sits at 33% of that range, 42.3% below the 52-week high.
EDIT latest news & SEC filings
Every SEC filing by or about EDIT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 9, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 9, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Burkly Linda sold 709 shares at $3.04 (≈$2.16K) on Sep 3, 2026
- Burkly Linda sold 709 shares at $3.04 (≈$2.16K) on Sep 3, 2026
- Burkly Linda sold 709 shares at $3.04 (≈$2.16K) on Sep 3, 2026
- Burkly Linda sold 709 shares at $3.04 (≈$2.16K) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Parison Amy sold 453 shares at $3.04 (≈$1.38K) on Sep 3, 2026
- Parison Amy sold 453 shares at $3.04 (≈$1.38K) on Sep 3, 2026
- Parison Amy sold 453 shares at $3.04 (≈$1.38K) on Sep 3, 2026
- Parison Amy sold 453 shares at $3.04 (≈$1.38K) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- O'Neill Gilmore Neil sold 5,124 shares at $3.04 (≈$15.58K) on Sep 3, 2026
- O'Neill Gilmore Neil sold 5,124 shares at $3.04 (≈$15.58K) on Sep 3, 2026
- O'Neill Gilmore Neil sold 5,124 shares at $3.04 (≈$15.58K) on Sep 3, 2026
- O'Neill Gilmore Neil sold 5,124 shares at $3.04 (≈$15.58K) on Sep 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 31, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 31, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $11.89M (prior year $3.58M) (+232.3% vs Jun 30, 2025)
- Net income: -$18.23M (prior year -$53.23M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.15 (prior year -$0.63) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade EDIT
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Mar 9, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.31% (largest 11.1%). That is a volatile stock.
- Liquidity: about 2.61M shares (≈$6.13M) trade per day on average.
- 52-week position: $2.35 vs a range of $1.66–$4.33 (26% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Linda Burkly sold 709 shares on Sep 3, 2026.
- Latest filings: 8-K Oct 8, 2026; 10-Q Aug 5, 2026; 8-K Aug 5, 2026.
- Share count: 153.58M shares outstanding (Jul 31, 2026), +70.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
EDIT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.44 | 2.47 | 2.33 | 2.35 | 1.55M |
| Oct 15, 2026 | 2.26 | 2.46 | 2.25 | 2.44 | 1.86M |
| Oct 14, 2026 | 2.44 | 2.47 | 2.24 | 2.27 | 2.83M |
| Oct 13, 2026 | 2.73 | 2.73 | 2.44 | 2.44 | 2.45M |
| Oct 12, 2026 | 2.90 | 2.91 | 2.73 | 2.75 | 1.30M |
| Oct 9, 2026 | 2.85 | 2.97 | 2.71 | 2.90 | 3.09M |
| Oct 8, 2026 | 2.79 | 2.94 | 2.69 | 2.84 | 6.07M |
| Oct 7, 2026 | 2.71 | 2.85 | 2.66 | 2.75 | 2.26M |
| Oct 6, 2026 | 2.85 | 2.89 | 2.71 | 2.73 | 2.97M |
| Oct 5, 2026 | 2.62 | 2.81 | 2.56 | 2.79 | 3.01M |
| Oct 2, 2026 | 2.57 | 2.63 | 2.51 | 2.62 | 2.16M |
| Oct 1, 2026 | 2.61 | 2.62 | 2.52 | 2.52 | 1.54M |
| Sep 30, 2026 | 2.61 | 2.72 | 2.55 | 2.57 | 1.62M |
| Sep 29, 2026 | 2.54 | 2.62 | 2.51 | 2.59 | 1.57M |
| Sep 28, 2026 | 2.55 | 2.55 | 2.42 | 2.51 | 2.20M |
| Sep 25, 2026 | 2.76 | 2.78 | 2.57 | 2.58 | 3.12M |
| Sep 24, 2026 | 2.66 | 2.76 | 2.55 | 2.75 | 2.59M |
| Sep 23, 2026 | 3.12 | 3.14 | 2.67 | 2.69 | 5.16M |
| Sep 22, 2026 | 2.86 | 2.93 | 2.81 | 2.92 | 2.29M |
| Sep 21, 2026 | 2.76 | 2.89 | 2.69 | 2.83 | 2.49M |
About Editas Medicine
Editas Medicine (EDIT) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1650664.
EDIT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Bernadette Connaughton | Director | Jun 22, 2026 |
| Patrick Thomas Ii Ellinor | Director | Aug 7, 2026 |
| Andrew Hirsch | Director | Jun 22, 2026 |
| Jessica Hopfield | Director | Jun 22, 2026 |
| Elliott M. Levy | Director | Jun 22, 2026 |
| Gilmore Neil O'Neill | CEO | Sep 4, 2026 |
| David Scadden | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sep 4, 2026 |
| Gilmore Neil O'Neill | CEO | Sep 4, 2026 |
| Daniel Scott Ory | EVP, Chief Medical Officer | Sep 9, 2026 |
| Amy Parison | SVP, Chief Financial Officer | Sep 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | Linda Burkly | Sale | 709 | $3.04 |
| Sep 3, 2026 | Linda Burkly | Sale | 709 | $3.04 |
| Sep 3, 2026 | Linda Burkly | Sale | 709 | $3.04 |
| Sep 3, 2026 | Linda Burkly | Sale | 709 | $3.04 |
| Sep 3, 2026 | Gilmore Neil O'Neill | Sale | 5,124 | $3.04 |
| Sep 3, 2026 | Gilmore Neil O'Neill | Sale | 5,124 | $3.04 |
| Sep 3, 2026 | Gilmore Neil O'Neill | Sale | 5,124 | $3.04 |
| Sep 3, 2026 | Gilmore Neil O'Neill | Sale | 5,124 | $3.04 |
| Sep 3, 2026 | Amy Parison | Sale | 453 | $3.04 |
| Sep 3, 2026 | Amy Parison | Sale | 453 | $3.04 |
| Sep 3, 2026 | Amy Parison | Sale | 453 | $3.04 |
| Sep 3, 2026 | Amy Parison | Sale | 453 | $3.04 |
| Aug 3, 2026 | Amy Parison | Sale | 678 | $2.58 |
| Aug 3, 2026 | Amy Parison | Sale | 678 | $2.58 |
| Aug 3, 2026 | Amy Parison | Sale | 678 | $2.58 |
EDIT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $40.52M | $-160.06M | -1.80 | $-165.24M |
| Dec 31, 2024 | $32.31M | $-237.09M | -2.88 | $-210.28M |
| Dec 31, 2023 | $78.12M | $-153.22M | -2.02 | $-132.18M |
| Dec 31, 2022 | $19.71M | $-220.43M | -3.21 | $-177.35M |
| Dec 31, 2021 | $25.54M | $-192.50M | -2.85 | $-163.80M |
Latest balance sheet: total assets $237.36M, total liabilities $132.08M, cash $181.81M (as of Jun 30, 2026).
EDIT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $2.75 |
| May 5, 2026 | 8-K Item 2.02 (results) | $3.04 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $2.32 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $2.52 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $2.29 |
| May 12, 2025 | 8-K Item 2.02 (results) | $1.54 |
| Mar 5, 2025 | 8-K Item 2.02 (results) | $2.05 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $1.16 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $2.88 |
| Oct 22, 2024 | 8-K Item 2.02 (results) | $3.29 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on EDIT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.